Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney ...

Its research pipeline targets six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC, with the aim of becoming a global leader in drug research and development.

One such mechanism involves a protein called p53. Often dubbed the "guardian of the genome," this protein plays a pivotal role in ensuring that your cells grow, divide and die in an orderly fashion.

Growth inhibition by TAS102 plus regorafenib occurs in xenografted tumors regardless of p53, KRAS or BRAF mutations, although more potent tumor suppression was observed with wild-type p53.

No one really understands why activation of the tumor suppressor p53 sometimes leads to cell-cycle arrest and sometimes induces an apoptotic program. It has been proposed that post-translational ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.

"This is an exciting and transformational year for Frontier Medicines as we look forward to interim clinical data for FMC-376, our novel dual KRAS G12C inhibitor, and move our second development ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...